canada clinical guidance

Perinatal mental health — recognition, safe prescribing, and referral

A Canadian clinical summary of perinatal mental health — recognition, safe prescribing, and referral, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team · Clinical editorial review · reviewed 2026-08-20 · due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Guideline No. 454: Identification and Treatment of Perinatal Mood and Anxiety Disorders. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:SOGC 454

Source-attributed clinical priorities

  • Screen and assess depression, anxiety, bipolar disorder, psychosis, substance use, trauma, suicide risk and infant safety during pregnancy and postpartum.
  • Balance untreated-illness risk with medication and therapy evidence through shared decisions rather than stopping effective treatment abruptly.
  • Treat postpartum psychosis, mania or imminent safety risk as an emergency and coordinate obstetric, psychiatric and infant care.
  • Screen for bipolar history before treating perinatal depression because postpartum mania risk changes the plan.
sources for this section:SOGC 454

Practical assessment and management workflow

1
Assess mood, anxiety, sleep beyond infant care, intrusive thoughts, psychosis, trauma, substances and supports.
2
Clarify suicide, infant-harm thoughts, intent, insight and ability to provide safe care.
3
Balance illness relapse against fetal, neonatal and breastfeeding medicine considerations with shared decisions.
4
Arrange proactive pregnancy and postpartum follow-up involving obstetric, primary and mental-health teams.
sources for this section:SOGC 454

Safety, red flags and urgent escalation

  • Postpartum psychosis, mania, severe depression or intent to harm self or infant is an emergency.
  • Do not stop a stable psychotropic abruptly solely because of pregnancy.
  • Distinguish unwanted ego-dystonic intrusive thoughts from psychotic beliefs while taking all safety concerns seriously.
sources for this section:SOGC 454

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:SOGC 454

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:SOGC 454

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Society of Obstetricians and Gynaecologists of CanadaGuideline No. 454: Identification and Treatment of Perinatal Mood and Anxiety Disordersaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.